scholarly journals Role of inflammation in previously untreated macular edema with branch retinal vein occlusion

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Hidetaka Noma ◽  
Tatsuya Mimura ◽  
Katsunori Shimada
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Vein Occlusion

Role of the Vitreous and Macular Edema in Branch Retinal Vein Occlusion

1997 ◽  
Vol 28 (4) ◽  
pp. 294-299
Author(s):  
Masatoshi K Takihashi ◽  
Taiichi Hikichi ◽  
Jun Akiba ◽  
Akitoshi Yoshida ◽  
Clement L Trempe
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Vein Occlusion

scholarly journals Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Hidetaka Noma ◽  
Kanako Yasuda ◽  
Masahiko Shimura
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Vascular Endothelial ◽  
Intraocular Injection ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Lifestyle Related Diseases ◽  
Endothelial Growth Factor

Branch retinal vein occlusion (BRVO) is a very common retinal vascular problem in patients with lifestyle-related diseases, such as hypertension and arteriosclerosis. In patients with BRVO, development of macular edema is the main cause of visual impairment. BRVO is still a controversial condition in many respects. Over the years, various methods such as laser photocoagulation have been tried to treat macular edema associated with BRVO, but the results were not satisfactory. After vascular endothelial growth factor (VEGF) was found to have an important role in the pathogenesis of macular edema in BRVO patients, treatment of this condition was revolutionized by development of anti-VEGF therapy. Although macular edema improves dramatically following intraocular injection of anti-VEGF agents, repeated recurrence and resistance of edema is a major problem in some BRVO patients. This suggests that factors or cytokines other than VEGF may be associated with inflammation and retinal hypoxia in BRVO and that the pathogenesis of macular edema is complicated. The present review assesses the role of various factors and cytokines in the pathogenesis of macular edema associated with BRVO. We present a mechanism that is not only plausible but should also be useful for developing new therapeutic strategies.

scholarly journals Relationship between recurrence of macular edema due to branch retinal vein occlusion and changes in choroidal thickness

2020 ◽  
Author(s):  
Yoshihito Sakanishi ◽  
Kazunori Tamaki ◽  
Keitaro Mashimo ◽  
Toshiro Sakuma ◽  
Nobuyuki Ebihara
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Case Series ◽  
Vascular Endothelial ◽  
Vein Occlusion ◽  
Intravitreal Aflibercept ◽  
Before And After ◽  
Endothelial Growth Factor

Introduction: The role of vascular endothelial growth factor (VEGF) in macular edema due to branch retinal vein occlusion by enhancing vascular permeability has been well studied. Macular edema due to branch retinal vein occlusion often recurs; however, there has been no report on the relationship between this recurrence and choroid thickness (CT), considering the high vascularity of the choroid. This study was designed to investigate this relationship. Methods: In this retrospective consecutive case series, patients with recurrence of macular edema within 6 months of receiving intravitreal aflibercept injection treatment for naive macular edema due to branch retinal vein occlusion at Juntendo University Urayasu Hospital were included. Retinal thickness (RT) and CT were measured in the fovea and on the occlusion, non-occlusion, nasal, and temporal sides at baseline, after the first intravitreal aflibercept administration, and before and after recurrence. We also examined the change for each side before and after reinjection. Results: This study included 11 patients and 11 eyes. The subfoveal CT and RT at baseline were 261.9±93.4 μm and 691.5±254.4 μm, respectively, which significantly decreased to 208.5±70.3 μm and 188.6±33.8 μm, respectively, at 1 month after the first injection (p=0.001 and p<0.01, respectively). These values also significantly decreased at all the other sites after treatment. There were 14 recurrences within the 6 months following intravitreal aflibercept injection; RT significantly changed at all sites before and after recurrence and reinjection. CT significantly changed at the subfovea and on the occlusion and non-occlusion sides; however, there was no significant change on the nasal and temporal sides. Conclusion: In patients with branch retinal vein occlusion, the CT around the macula after initial treatment was significantly reduced; however, at the time of macular edema recurrence and reinjection, there were site-dependent differences in the changes observed in the CT. These findings suggest that the pathologies of macular edema at initial occurrence and at the time of recurrence are different.

scholarly journals Relationship between metamorphopsia and inner retinal microstructure following intravitreal ranibizumab injection for branch retinal vein occlusion

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoshimi Sugiura ◽  
Fumiki Okamoto ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Takahiro Hiraoka ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Post Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Treatment Naïve ◽  
Pre Treatment ◽  
Number Of Injections

AbstractTo evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the relationship between metamorphopsia and inner retinal microstructure and other factors. Thirty-three treatment-naïve eyes of 33 patients with macular edema caused by BRVO with at least 12 months of follow-up were included. The degree of metamorphopsia was quantified using the M-CHARTS. Retinal microstructure was assessed with spectral-domain optical coherence tomography. Disorganization of the retinal inner layers (DRIL) at the first month after resolution of the macular edema (early DRIL) and at 12 months after treatment (after DRIL) was studied. Central retinal thickness (CRT), and status of the external limiting membrane as well as ellipsoid zone were also evaluated. IVR treatment significantly improved best-corrected visual acuity (BCVA) and CRT, but the mean metamorphopsia score did not improve even after 12 months. Post-treatment metamorphopsia scores showed a significant correlation with pre-treatment metamorphopsia scores (P < 0.005), the extent of early DRIL (P < 0.05) and after DRIL (P < 0.05), and the number of injections (P < 0.05). Multivariate analysis revealed that the post-treatment mean metamorphopsia score was significantly correlated with the pre-treatment mean metamorphopsia score (P < 0.05). IVR treatment significantly improved BCVA and CRT, but not metamorphopsia. Post-treatment metamorphopsia scores were significantly associated with pre-treatment metamorphopsia scores, the extent of DRIL, and the number of injections. Prognostic factor of metamorphopsia was the degree of pre-treatment metamorphopsia.

Sign in / Sign up

Export Citation Format

Share Document